Systemic Antifungal Therapy: New Options, New Challenges

Pharmacotherapy

Volumn 23, Issue 11, 2003, Pages 1441-1462

  Wong Beringer, Annie ^a,b   Kriengkauykiat, Jane ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTACID AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN B DERIVATIVE; EFAVIRENZ; ERGOT ALKALOID; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NEVIRAPINE; PHENYTOIN; POSACONAZOLE; PROTON PUMP INHIBITOR; RAPAMYCIN; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANIMAL; ASPERGILLOSIS; BRONCHOSPASM; CANDIDIASIS; CHILL; CLINICAL TRIAL; COLOR VISION DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESISTANCE; ECONOMICS; EDEMA; ERYTHEMA; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HUMAN; HYPOKALEMIA; HYPOTENSION; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; METABOLISM; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY DISORDER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME; VISUAL IMPAIRMENT; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HUMANS; MYCOSES; NEUTROPENIA;

EID: 0142182539     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.14.1441.31938     Document Type: Review

References (118)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
2. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
3. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. Clin Infect Dis 2001;33:177-86.
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systemic review of the literature. Clin Infect Dis 2001;32:358-66.
5. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
6. Marr K, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
7. Maertens J, Raad I, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations, or azoles [abstr]. In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 17-20, 2000. Washington, DC: American Society for Microbiology, 2000:371.
8. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
9. Terell C. Antifungal agents. II. The azoles. Mayo Clin Proc 1999;74:78-100.
10. Patel R. Antifungal agents. I. Amphotericin B preparations and flucytosine. Mayo Clin Proc 1998;73:1205-25.
11. White T, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
12. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(suppl):S37-41.
13. Gubbins PO, Penzak SR, Polston S, McConnell SA, Anaissic E. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002;22:961-71.
14. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.
15. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphoterictn B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18.
16. Ellis M, Shamoon A, Gorka W, et al. Severe hepatic injury associated with lipid formulations of amphotericin B. Clin Infect Dis 2001;32:E87-9.
17. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
18. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21.
19. Espinel-Ingroff A. In vitro activity of the new triazole, voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common yeast pathogens. J Clin Microbiol 1998;36:198-202.
20. Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999;43:169-70.
21. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 1999;34:1463-4.
22. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000;44:1734-6.
23. Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996;22:336-40.
24. Pfaller MA, Messer SA, Hollis RJ, Jones RN, for the Sentry Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of intraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002;46:1032-7.
25. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2.
26. Grasela DM, Olsen SJ, Mummaneni V, et al. Ravuconazole: multiple ascending oral dose study in healthy subjects [abstr]. In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 17-20, 2000. Washington, DC: American Society for Microbiology, 2000:839.
27. Olsen SJ, Mummaneni V, Rolan P, Norton J, Grasela DM. Ravuconazole single ascending oral dose study in healthy subjects [abstr]. In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 17-20, 2000. Washington, DC: American Society for Microbiology, 2000:838.
28. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-44.
29. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002;46:1704-13.
30. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001;35:720-9.
31. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999;19:603-11.
32. Johnson MD, Hamilton CD, Drew RH, et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003;51:453-7.
33. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 2000;38:111-80.
34. Fromm MF, Kauffman HM, Fritz P, et al. The effect of rifampin on intestinal expression of human MRP transporters. Am J Pathol 2000;157:1575-80.
35. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;4:14581-7.
36. Food and Drug Administration. Voriconazole background document for the antiviral drug products advisory committee meeting. NDAs 21-266 and 21-267. Food and Drug Administration, Center for Drug Evaluation and Research. Division of Special Pathogen and Immunologic Drug Products, Oct 4, 2001. Available from http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02FDA-voriconazole.pdf or http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2.htm. Accessed February 28, 2003.
37. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-7.
38. Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998;36:1436-8.
39. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconzole [letter]. Brit J Ophthalmol 2000;84:932-3.
40. Meletiadis J, Meis JFGM, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002;46:62-8.
41. Machetti M, Zotti M, Veroni L, et al. Case report: antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000;2:140-4.
42. Poza G, Montoya J, Redondo C, et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 2000;30:981-2.
43. Jezequel SG, Clark M, Evans K, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in animals [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 17-20, 1995. Washington DC: American Society for Microbiology, 1995:F77.
44. Scwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997;97:663-5.
45. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous-to-oral dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53.
46. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002;42:393-400.
47. Pfizer. Vfend (voriconazole) package insert. New York, NY; 2002.
48. Food and Drug Administration. Briefing document for voriconazole. FDA Antiviral Drugs Advisory Committee October 4, 2001. Available from http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3 792b2_01_Pfizer.pdf. Accessed February 28, 2003.
49. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55.
50. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3.
51. Romero Aj, Le Pogamp P, Nillsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
52. Denning DW, Griffiths CEM. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exper Derm 2001;26:648-53.
53. Tan KKC, Brayshaw N, Oakes M. Investigation of the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials [abstr]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology, 2001:A-18.
54. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273-5.
55. Denning DW, Ribaud P, Milped N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
56. Tomaszewski K, Purkins L. Visual effects with voriconazole [abstr]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology, 2001:A-639.
57. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57.
58. Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immuno-suppressed mice. Antimicrob Agents Chemother 2000;43:2310-18.
59. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999;33:75-80.
60. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2326-32.
61. Barchiesi F, Schmizzi AM, Fothergill AW, Scalise G, Rinaldi MG. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999;18:302-4.
62. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:1985-9.
63. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997;41:2333-8.
64. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000;182:1791-5.
65. van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 2002;46:3394-400.
66. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998;32:33-7.
67. Moore CB, Denning DW. Tolerance and fungicidality in vitro of caspofungin, micafungin, and anidulafungin against Candida guillermondii [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemo-therapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology, 2002:M-230.
68. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-80.
69. Ramage G, Vande Walle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002;46:3634-6.
70. Bachmann SP, Ramage G, Fothergill AW, et al. Combinations of antifungal agents against Candida albicans biofilms in vitro [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology. 2002:M-1813.
71. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-βD-Glucan synthase. Antimicrob Agents Chemother 1994;38: 1480-9.
72. Oshaughnessy EM, Peter J, Walsh TJ. In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology, 2002:M-856.
73. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002;46:245-7.
74. Chandrasekar PH, Cutright JL, Manavathu EK. In vitro activity of amphotericin B lipid complex in 2-drug combination with caspofungin against Aspergillus fumigatus [abstr]. In: Program and abstracts of the focus on fungal infections meeting 12, Phoenix, AZ, March 20-22, 2002. Alpharetta, GA: Imedex, 2002.
75. Perea S, Gonzalez G, Fothergill AW, et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002;46:3039-41.
76. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46:2564-8.
77. Kontoyiannis DP, Lewis RE, Osherov N, et al. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003;51:313-16.
78. Food and Drug Administration. Caspofungin acetate for injection (Cancidas). Medical review. NDA 21-227. Center for Drug Evaluation and Research. Available from http://www.fda.gov/cder/foi/nda/2001/21227_Cancidas.htm. Accessed February 28, 2003.
79. Stone J, Holland S, Wickersham P, et al. Drug interactions between caspofungin and tacrolimus [abstr]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology, 2001:A-13.
80. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
81. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429-35.
82. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
83. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002;40:3551-7.
84. Luber AD, Maa Lucy, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999;43:267-71.
85. Anaissie EJ, White M, Uzun O, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 17-20, 1995. Washington, DC: American Society for Microbiology, 1995:LM21.
86. Rex JH, Bennet JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
87. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001;44:125-35.
88. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
89. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6.
90. Zerr DM, Garrison MM, Marr KA, Christakis DA. A meta-analysis of fluconazole versus amphotericin B for treatment of invasive Candida infections. J Clin Outcomes Manage 2002;9:191-6.
91. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;224:235-47.
92. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8.
93. Revankar SG, Kirkpatrick WR, McAtee RK, et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 1998;36:153-6.
94. Food and Drug Administration. Voriconazole (Vfend) NDA 21-266 and 21-267. Center for Drug Evaluation and Research. Available from http://www.fda.gov/cder/foi/nda/2002/21-266_21-267_VFEND.htm. Accessed February 28, 2003.
95. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31.
96. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-805.
97. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 2000;79:250-60.
98. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
99. Maertens J, Raad I, Petrikkos G, et al. Update of multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology, 2002:M-856.
100. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
101. Thiebaut A, Antal D, Breysse MC, Pivot C. Refractory invasive fungal infections in patients (pts) with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology, 2002:M-859.
102. Gentina T, De Botton S, Alfandari S, et al. Combination antifungals for treatment of pulmonary invasive aspergillosis (IA) refractory to amphotericin B (AmB) in leukaemia patients [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology, 2002:M-860.
103. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of the caspofungin/liposomal amphotericin B (CAS/LipoAMB) combination in documented or possible invasive aspergillosis (IA) in patients (pts) with hematologic malignancies [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27-30, 2002. Washington, DC: American Society for Microbiology, 2002:M-1820.
104. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
105. Ninin E, Milpied N, Moreau P, et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001;33:41-7.
106. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
107. Marr K, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
108. Revanker SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin infect Dis 2002;34:467-76.
109. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476-83.
110. Winston DJ, Hatborn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9.
111. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized control trial. Ann Intern Med 2001;135:412-22.
112. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
113. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63.
114. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-5.
115. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empiric antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
116. Food and Drug Administration. FDA presentation on NDA 21-266, Vfend (voriconazole) tablets, and NDA 21-267, Vfend I.V. (voriconazole) for infusion. Food and Drug Administration Antiviral Drugs Advisory Committee (AVAC) Meeting, Oct 4, 2001. Available from http://www.fda.gov/ohrms/dockets/ac/01/slides/3792s2.htm. Accessed February 28, 2003.
117. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002;49(suppl 1):31-6.
118. Janssen Pharmaceutica Products, L.P. Sporanox (itraconazole) package insert. Titusville, NJ; 2002.